rs854572 — PON1 PON1 promoter -909G>C

PON1 Promoter -909G>C — A Secondary Regulator of Your HDL's Antioxidant Enzyme Output

The paraoxonase-1 (PON1) gene produces an enzyme that travels on HDL particles¹¹ HDL particles
High-density lipoprotein — the so-called "good cholesterol," which carries cholesterol from peripheral tissues to the liver and provides antioxidant protection in the arterial wall and acts as the bloodstream's primary defense against oxidized LDL — the form of "bad cholesterol" that initiates plaque buildup in artery walls. Three polymorphisms in the PON1 promoter region jointly regulate how much of this enzyme your liver produces: -108C/T (rs705379), -162A/G (rs705381), and -909G/C (rs854572). While the -108 position is the strongest single predictor of expression levels, the -909 variant tagged by rs854572 contributes independently to inter-individual variation and participates in the overall promoter haplotype.

The Mechanism

The PON1 gene sits on the minus (reverse) strand of chromosome 7q21.3. In the promoter region 909 base pairs upstream of the coding sequence, a G-to-C transition (reported as C>G in plus-strand genome files) alters a regulatory element that influences PON1 transcription. Functional studies by Brophy et al. (2001)²² Brophy et al. (2001)
Brophy VH et al., Pharmacogenetics 2001 demonstrated that the -909, -162, and -108 polymorphisms each have approximately a 2-fold effect on PON1 expression in reporter gene assays, though their effects appear context-dependent and not strictly additive. In a larger population study, the -909 variant showed strong linkage disequilibrium with the -108 and -162 sites, with no significant independent in vivo effect detectable in isolation in white individuals — suggesting that most of its influence on PON1 activity is propagated through the haplotype it tags rather than through a fully autonomous regulatory element.

However, expanded genetic analysis of the PON gene cluster by Carlson et al. (2012)³³ Carlson et al. (2012)
Carlson CS et al., Circ Cardiovasc Genet 2012 identified rs854572 as the lead SNP for arylesterase activity in a multi-SNP model, with the minor allele increasing activity by approximately 16% per copy — a finding that held even after accounting for the four classical functional SNPs (L55M, Q192R, -108, and -162). This suggests rs854572 captures regulatory variance that the other known variants do not fully explain, even if its independent effect is modest compared to the -108 position.

The Evidence

The clinical consequences of the -909 haplotype have been examined in cardiovascular, neurological, and ocular contexts.

In a prospective study of young coronary patients, Deakin et al. (2002)⁴⁴ Deakin et al. (2002) found that high-expressor PON1 promoter genotypes — including the -909 GG genotype (coding strand notation) — were associated with reduced risk of vascular disease in patients under age 60, consistent with higher promoter-driven PON1 output providing meaningful protection during the critical period of atherosclerotic plaque initiation.

In a measure of serum PON1 concentration in 417 coronary heart disease patients and 282 controls, PON1 concentration in the CHD group differed significantly by -909 genotype in the order GG > GC > CC (coding-strand notation), confirming the expression gradient this promoter variant creates.

A nutrigenetic study by Mancini et al. (2016)⁵⁵ Mancini et al. (2016)
Journal of Translational Medicine found rs854572 protective genotypes were significantly associated with increased HDL cholesterol levels specifically under high polyphenol and anthocyanin intake — suggesting an important gene-diet interaction where the expression effect of this variant is amplified in high-polyphenol dietary contexts. The association reached Bonferroni significance (Beta = 3.94 per protective allele).

Neurologically, rs854572 was highlighted as being in strong LD with rs854571, itself significantly associated with Parkinson's disease protection (p = 0.007) — Belin et al. (2012)⁶⁶ Belin et al. (2012)
Neuroscience Letters specifically noted rs854572 as reported to increase PON1 gene expression, and proposed the two variants together define the high-expression haplotype associated with neuroprotection.

Importantly, despite these activity associations, larger studies including Carlson et al. (2012)⁷⁷ Carlson et al. (2012) found no significant association between rs854572 and vascular disease endpoints (coronary artery disease, myocardial infarction) in population-level analyses. This suggests the modulation of PON1 activity by this variant is real, but insufficient alone to translate to detectable disease-level effects in unselected populations — the overall activity difference may require compounding with other PON1 variants or environmental exposures to reach clinical threshold.

Practical Implications

Because rs854572 operates as part of the broader PON1 promoter haplotype, its practical importance is highest in individuals who also carry unfavorable -108 or -162 variants, or the low-activity coding variants Q192R (rs662) or L55M (rs854560). For GG individuals (the low-expression plus-strand genotype), the priority interventions are those that upregulate PON1 expression through dietary means.

Dietary polyphenols have been shown in multiple controlled studies to increase PON1 expression and arylesterase activity — pomegranate juice, extra virgin olive oil, green tea, and quercetin-rich vegetables are the best-documented sources. The nutrigenetic study by Mancini et al. (2016) provides specific evidence that rs854572 carriers respond to polyphenol intake with measurable HDL changes, making dietary optimization particularly relevant for this genotype.

Interactions

rs854572 operates within the three-variant PON1 promoter haplotype block alongside rs854571 (immediately adjacent, also a promoter regulatory SNP) and rs705379 (-108C/T, the strongest determinant of PON1 expression). These promoter variants collectively control how much PON1 is produced, independently of the coding variants rs662 (Q192R, which controls enzyme catalytic specificity) and rs854560 (L55M, which affects protein stability and circulating concentrations). Individuals carrying unfavorable variants across all five PON1 positions represent the lowest-activity phenotype. The combined effect of this promoter variant with rs662 and rs854560 is of particular interest for compound action consideration, as the promoter-coding interaction determines both the quantity and quality of available PON1 enzyme simultaneously.